AbbVie today announced that its investigational direct-acting antiviral combination with and without ribavirin for the treatment of genotype 1 hepatitis C virus infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration .
http://www.pmpnews.com/news/abbvies-investigational-hcv-regimen-receives-breakthrough-therapy-designation-us-food-and-dru-0
http://www.pmpnews.com/news/abbvies-investigational-hcv-regimen-receives-breakthrough-therapy-designation-us-food-and-dru-0
